CELESTIAL

Celestial Biolabs Limited has informed the Exchange that ''We are already manufacturing and marketing Premium products In Herbal and Nutraceuticals range. In view of our established marketing & distribution network in India, we have decided to introduce manufacturing and marketing of 21 life saving drugs in Allopathic range covering,. Antibiotics, Analgesic & Anti-pyretics; Antiulcerants; Anti-Hypertensives; Anti-Diabetics; Anti-Fungal; Anti-Allergic; Anti-Emetic; Calcium Supplement; Steroid; Immune Suppressant and Topical Application for Wound Infection & Neurological disorders.This will enha

Celestial Biolabs Limited has informed the Exchange regarding voting results for the Annual General Meeting of the Company held on November 28, 2015.

Celestial Biolabs Limited has submitted to the exchange the standalone financial results for the period ended 30-Sep-2015.

Celestial Biolabs Limited has informed the Exchange that the Register of Members and Share Transfer Books of the Company shall remain closed from November 26, 2015 to November 28, 2015 (both days inclusive) for the purpose of Annual General Meeting scheduled to be held on November 28, 2015.

Celestial Biolabs Limited has informed the Exchange that the Board of Directors in their Board Meeting held on October 22, 2015 have decided, subject to approval from shareholders, stock exchanges or any statutory body as may be required in this regard, to issue 21,00,000 convertible warrants on preferential basis to promoters & non promoter group.

Celestial Biolabs Limited has informed the Exchange that the Company has completed successfully pre-clinical study on mouse for finding out toxicity and efficacy for Herbal Biovita (A health drink). Human controlled clinical trial shall start in phases to complete the Dozier so that we can place this product globally. Biovita has been accepted by Indian market very well.

Celestial Biolabs Limited has informed the Exchange that in accordance with the provisions of Section 96(1) of the Companies Act, 2013 Company have obtained extension of time for convening the Annual General Meeting for the financial year 2014-15 upto 3 months (i.e.,upto December 31, 2015) from the Registrar of Companies, Ministry of Corporate Affairs vide their letter dated September 07, 2015.

Celestial Biolabs Limited has submitted to the exchange the standalone financial results along with the Limited Review Report for the period ended 30-Jun-2015.

Celestial Biolabs Limited has informed the Exchange that the Board of Directors had in their meeting held on July 02, 2015 have considered and adopted the revised Balance Sheet as on March 31, 2015 due the reason of regrouping of accounts.

Celestial Biolabs Limited has submitted to the exchange the standalone financial results for the period ended 31-Mar-2015.

Dr. A.N.Singh has submitted to the Exchange vide letter dated April 10, 2015 a copy of disclosure under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Celestial Biolabs Limited has submitted to the exchange the standalone financial results for the period ended 31-Dec-2014.

Celestial Biolabs Limited has informed the Exchange that the Board of Directors in their Board meeting held on January 22, 2015 have transacted the following business : Allotted 12,05,350 equity shares of Rs.10/- each as Sweat Equity Shares(Fourth Tranche) to Dr. A. N. Singh, Chairman and Managing Director of the Company.

Celestial Biolabs Limited has informed the Exchange vide letter dated January 12, 2015 regarding "Celestial To Launch Patented Anti-Diabetic Product".

Celestial Biolabs Limited has informed the Exchange regarding the outcome of Voting result of the Annual General Meeting of the Company held on November 15, 2014

Celestial Biolabs Limited has submitted to the exchange the standalone financial results for the period ended 30-Sep-2014.

Celestial Biolabs Limited has informed the Exchange that the Register of Members & Share Transfer Books will remain closed from November 13, 2014 to November 15, 2014 (both days inclusive) for the purpose of Annual General Meeting for the financial year 2013-2014 scheduled to be held on November 15, 2014.

Celestial Biolabs Limited has informed the Exchange that in accordance with the provisions of Section 96(1) of the Companies Act, 2013 the Company have obtained extension of time for convening the Annual General Meeting for the financial year 2013-14 upto 3 months (i.e., upto December 31, 2014) from the Registrar of Companies, Ministry of Corporate Affairs vide their letter dated September 05, 2014.

Padma Singh has submitted to the Exchange vide letter dated August 28, 2014 a copy of Disclosure in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Rangoli Commodeal Pvt. Ltd. has submitted to the Exchange, vide its letters August 26, 2014 a copy of disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Celestial Biolabs Limited has submitted to the exchange the standalone financial results for the period ended 30-Jun-2014.

Celestial Biolabs Limited has informed the Exchange that Celestial Biolabs Ltd Hyderabad has launched Cadalmin Gae, a marine derived, developed, formulated clinically tested and patented natural product to treat arthritis ( all kinds of joint pain). The product has received remarkable response from doctors as well as patients. The product is very effective, safe and vegetarian. The product is quite affordable as the selling price of the product is 1/ 3rd of the chemically derived medicine available in the market being used for arthritis. In order to reach to all the affected people suffering

Celestial Biolabs Limited has submitted to the exchange the standalone financial results for the period ended 31-Mar-2014.

Dr. A N Singh has submitted to the Exchange vide its letter dated April 04, 2014 a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Celestial Biolabs Limited has informed the Exchange that this is to inform you that the Board of Directors in their meeting held on March 27, 2014 have allotted 12,50,000 equity shares of Rs.10/- each as Sweat Equity Shares(Third Tranche) to Dr A N Singh, Chairman and Managing Director of the Company in accordance with SEBI Guidelines.

Celestial Biolabs Limited has informed the Exchange that the Board of Directors in their Board meeting held on March 22, 2014 have 1. Allotted 15,00,000 equity shares of Rs.10/- each on preferential basis to promoter group and non promoter group in accordance with SEBI Guidelines. 2. Adjourned the Board meeting for allotment of the third tranche of sweat equity shares comprising of 12,50,000 equity shares to Dr A N Singh, Chairman and Managing Director.

Celestial Biolabs Limited has informed the Exchange regarding the voting results of items transacted at the Extra ordinary General Meeting of the Company held on February 20, 2014, in compliance of Clause 35A of the Listing Agreement.

Celestial Biolabs Limited has submitted to the exchange the standalone financial results for the period ended 31-Dec-2013.

Celestial Biolabs Limited has informed the Exchange that there was a typographical error in the EGM Notice & Postal Ballot resolution / explanatory statement with respect to the "Relevant Date" for issue of Sweat Equity Shares. The relevant date as mentioned in postal ballot resolution / explanatory statement to be read as January 21, 2014 instead of January 16, 2014.

Celestial Biolabs Limited has submitted to the Exchange a copy of the Postal Ballot Notice sent to the shareholders pursuant to Section 192A of the Companies Act, 1956 read with the Companies (Passing of the Resolutions by Postal Ballot) Rules, 2011.

Celestial Biolabs Limited has submitted to the Exchange a copy of notice of Extra-Ordinary General Meeting of the Bank to be held on February 20, 2014.

Celestial Biolabs Limited has submitted to the Exchange the outcome of the Board Meeting held on January 9, 2014

Celestial Biolabs Limited has submitted to the exchange the standalone financial results for the period ended 30-Sep-2013.

Celestial Biolabs Limited has informed the Exchange that consequent to the resignation of Mrs.T.A Veena from the office of Company Secretary, the Board of Directors have decided to appoint Mr. P.Ramakrishna, Finance Officer as Compliance officer of the company. Details are as follows: Name Mr. P.Ramakrishna Contact details # 59, Road # 12, Apiic Tech Park, IDA Nacharam, Hyderabad 500076 ramakrishna@celestialbiolabs.com 040-65552697/64565544

Celestial Biolabs Limited has submitted to the Exchange the outcome of Annual General Meeting held on September 19, 2013.

Celestial Biolabs Limited has informed the Exchange, vide letter dated September 19, 2013 a copy of corporate announcement titled "Launching of New Product - CADALMIN GAe".

Celestial Biolabs Limited has informed the Exchange that the Register of Members & Share Transfer Books will remain close from September 17, 2013 to September 19, 2013 (both days inclusive)for the purpose of Annual General Meeting of the Company to be held on September 19, 2013

Celestial Biolabs Limited has submitted to the Exchange the Standalone Financial Results for the period ended June 30,2013.

Celestial Biolabs Limited has submitted to the Exchange the Standalone Financial Results for the period ended March 31,2013.

Celestial Biolabs Limited has submitted to the Exchange the Standalone Financial Results for the period ended December 31,2012.

Celestial Biolabs Limited has submitted to the Exchange the Standalone Financial Results for the period ended September 30,2012.

Celestial Biolabs Limited has informed the Exchange regarding the Outcome of the Annual General Meeting of the Company held on September 29, 2012.

Celestial Biolabs Limited has informed the Exchange that the Register of Members and Share Transfer Books of the Company will remain closed from September 25, 2012 to September 29, 2012 (both days inclusive) for the purpose of Annual General Meeting of the Members scheduled to be held on September 29, 2012.

Celestial Biolabs Limited has informed the Exchange that the Board of Directors in the Board meeting held on September 03, 2012:(a) Have accepted the resignation of Dr D C Sastry as the Chairman and Director of the company with immediate effect.(b) Have appointed Dr A N Singh as the Chairman of the Company.(c) Have reconstituted the Audit Committee, Remuneration Committee and the Shareholders Grievance committee consequent to resignation of Dr D C Sastry.

Celestial Biolabs Limited has submitted to the Exchange the Standalone Financial Results for the period ended June 30,2012.

Nitin Kumar Singh has submitted to the Exchange vide its letter dated June 11, 2012 a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 along with disclosure under Regulation 13(4), 13(4A) and 13(6) of the SEBI (Prohibition of Insider Trading) Regulations, 1992.

Amit Kumar Singh has submitted to the Exchange vide its letter dated June 11, 2012 a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 along with disclosure under Regulation 13(4), 13(4A) and 13(6) of the SEBI (Prohibition of Insider Trading) Regulations, 1992.

Dr. A N Singh has submitted to the Exchange vide its letter dated June 11, 2012 a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 along with disclosure under Regulation 13(4), 13(4A) and 13(6) of the SEBI (Prohibition of Insider Trading) Regulations, 1992.

Celestial Biolabs Limited has submitted to the Exchange the Standalone Financial Results for the period ended March 31,2012.

Celestial Biolabs Limited has submitted to the Exchange a copy of the disclosure under Regulation 13(6) of SEBI (Prohibition of Insider Trading Regulations), 1992.